MedTrace Logo

JINZHEN for Treatment of Mild to Moderate COVID-19

NCT05092503 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-03-20

No results posted yet for this study

Summary

JINZHEN is a botanical drug that contains eight chemical constituents extracted from plant, mineral and animal origin raw materials. This study is to evaluate the safety and efficacy of JINZHEN Granules for Oral Solution compared to placebo for treatment of mild to moderate COVID-19 outpatients.

Conditions

Interventions

DRUG

JINZHEN Granules for Oral Solution

JINZHEN granules will be dissolved in drinking water and administered orally.

DRUG

Placebo

Placebo granules will be dissolved in drinking water and administered orally.

Sponsors & Collaborators

  • Lianyungang Kanion Group, Ltd.

    lead INDUSTRY

Principal Investigators

  • Zhu · Jiangsu Kanion Pharmaceutical Co., Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-26
Primary Completion
2023-05-12
Completion
2023-05-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05092503 on ClinicalTrials.gov